CN101279075A - Medicament for curing coronary heart disease - Google Patents
Medicament for curing coronary heart disease Download PDFInfo
- Publication number
- CN101279075A CN101279075A CNA2007100108459A CN200710010845A CN101279075A CN 101279075 A CN101279075 A CN 101279075A CN A2007100108459 A CNA2007100108459 A CN A2007100108459A CN 200710010845 A CN200710010845 A CN 200710010845A CN 101279075 A CN101279075 A CN 101279075A
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- heart disease
- coronary heart
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine for curing coronary heart disease and pertains to Chinese herbal medicine. The invention provides a medicine with good curative effect for coronary heart disease with symptoms of turbid phlegm and blood stasis caused by atherosclerosis. The invention adopts the technical proposal as follows: the medicine is prepared by 9-30g of codonopsis pilosula, 9-30g of astragalus hoangtchy, 9-20g of tuckahoe, 3-10g of prepared pinellia tuber, 3-10g of grassleaf sweetflag rhizome, 3-15g of hemlock parsley, 3-15g of radix curcumae, 5-15 g of salvia miltiorrhiza and 9-15g of gynostemma pentaphyllum.
Description
Technical field:
The present invention belongs to Chinese herbal medicine, is mainly used in the turbid blood stasis coronary heart disease of expectorant that the treatment atherosclerosis causes.
Background technology:
The Chinese medicine for the treatment of coronary heart disease in the market is of a great variety, as TONGXINLUO JIAONANG, and FUFANG DANSHEN DIWAN etc., the Chinese medicine thing is many based on blood circulation promoting and blood stasis dispelling, though also obtained reasonable clinical effectiveness, has ignored the turbid influence to blood stasis of expectorant; Even it is also many directly eliminating the phlegm to have contained the turbid square medicine to the blood stasis influence of expectorant, and ignored the Therapeutic Principle of invigorating the spleen and benefiting QI.Therefore, the therapeutic effect of coronary heart disease is unsatisfactory.
Summary of the invention:
The present invention is exactly at the problems referred to above, and a kind of eutherapeutic medicine of the turbid blood stasis type coronary heart disease of expectorant that atherosclerosis causes for the treatment of is provided.
The present invention adopts following technical scheme:
The present invention is by Radix Codonopsis 9～30g; The Radix Astragali 9～30g; Poria 9～20g; Rhizoma Pinelliae Preparatum 3～10g; Rhizoma Acori Graminei 3～10g; Rhizoma Chuanxiong 3～15g; Radix Curcumae 3～15g; Radix Salviae Miltiorrhizae 5～15g; Herb Gynostemmae Pentaphylli 9～15g makes.
Reuse Radix Codonopsis, Herb Gynostemmae Pentaphylli invigorating the spleen and benefiting QI in the present invention, Herb Gynostemmae Pentaphylli can spleen invigorating dehumidifying, to stop to give birth to the source of expectorant, again can preventing phlegm from forming and stopping coughing, with the device of respectful clean storage expectorant; Cooperate Poria can spleen invigorating again can eliminating dampness by diuresis, making wet do not have gather the expectorant life of having no way of; Treatment coronary heart disease is reached gets twice the result with half the effort.
Beneficial effect of the present invention:
1, we have reliable clinical efficacy.Confirm to have the atherosclerotic effect of control through sufficient animal infrastest and a large amount of clinical observations, thus the coronary heart disease that control is formed by atherosclerosis.
2, medicine of the present invention is formed simply, and flavour of a drug are few, and are cheap, are easy to be accepted by the patient.All adopt the granule dosage form in we's experimentation, can be converted into decoction, powder, pill etc.
3, basic research and clinical trial prove: the blood stasis dispersing and phlegm expelling prescription can be prevented arachidonic acid pathway, ADP approach, the inductive hematoblastic activation of thrombin approach, especially arachidonic acid pathway; α P that membrana granulosa discharges selects plain level after can reducing platelet activation, has reduced hematoblastic activation and thrombosis, and preventing with P selection element is the local inflammation reaction of mediation; Can improve vascular endothelial function; By suppressing hematoblastic activation, local inflammation reaction, improve the imbalance of vascular endothelial function, thereby prevent the process of AS.
The specific embodiment:
Embodiment 1:
Radix Codonopsis 25g, Radix Astragali 25g, Herb Gynostemmae Pentaphylli 15g, Poria 10g, Rhizoma Pinelliae Preparatum 5g, Rhizoma Acori Graminei 5g, Rhizoma Chuanxiong 5g, Radix Curcumae 5g, Radix Salviae Miltiorrhizae 5g form.
Embodiment 2:
Radix Codonopsis 20g, Radix Astragali 20g, Herb Gynostemmae Pentaphylli 15g, Poria 15g, Rhizoma Pinelliae Preparatum 5g, Rhizoma Acori Graminei 5g, Rhizoma Chuanxiong 10g, Radix Curcumae 10g, Radix Salviae Miltiorrhizae 10g form.
Embodiment 3:
Radix Codonopsis 15g, Radix Astragali 15g, Herb Gynostemmae Pentaphylli 15g, Poria 10g, Rhizoma Pinelliae Preparatum 5g, Rhizoma Acori Graminei 5g, Rhizoma Chuanxiong 15g, Radix Curcumae 15g, Radix Salviae Miltiorrhizae 15g form.
Embodiment 4:
Radix Codonopsis 10g, Radix Astragali 10g, Herb Gynostemmae Pentaphylli 15g, Poria 15g, Rhizoma Pinelliae Preparatum 5g, Rhizoma Acori Graminei 5g, Rhizoma Chuanxiong 15g, Radix Curcumae 10g, Radix Salviae Miltiorrhizae 10g form.
Embodiment 5:
Radix Codonopsis 10g, Radix Astragali 10g, Herb Gynostemmae Pentaphylli 15g, Poria 15g, Rhizoma Pinelliae Preparatum 5g, Rhizoma Acori Graminei 5g, Rhizoma Chuanxiong 15g, Radix Curcumae 15g, Radix Salviae Miltiorrhizae 15g form.
Embodiment 6:
Radix Codonopsis 10g, Radix Astragali 10g, Herb Gynostemmae Pentaphylli 15g, Poria 20g, Rhizoma Pinelliae Preparatum 10g, Rhizoma Acori Graminei 10g, Rhizoma Chuanxiong 15g, Radix Curcumae 15g, Radix Salviae Miltiorrhizae 15g form.
The manufacture method of this medicine:
More than ten flavor medicines, decoct with water, 1 hour for the first time, 50 minutes for the second time, filter, discard medicinal residues, merging filtrate, being concentrated into relative density is the clear paste of 1.08-1.13 (60 ℃), adds dextrin, correctives is an amount of, mixing, spray drying is made granule, promptly.
Clinical data
The object of observation and grouping: UAP96 example (hospitalization) all meets WH0 diagnostic criteria for coronary heart disease in 1979.Wherein male 61 examples, women 35 examples: 35～70 years old age, average (59.2 ± 10.0) year; Initial onset angina pectoris 20 examples, progressive angina pectoris 58 examples, angina pectoris decubitus 18 examples.Except: take lipid-regulation medicine and vitamin E in 4 weeks and treat antiinflammatory, the antioxidation medicine universe; Hypertension, diabetes, rheumatism, thyroid disease, acute myocardial infarction person; Serious hepatorenal disease person.
96 examples are divided into three groups at random: Western medicine contrast (B) group, Chinese medicine contrast (C) group, treatment by Chinese herbs (D) group, every group 32 example.Other establishes normal control (A) group 32 examples (health examination person), wherein male 20 examples, women 12 examples; 35～70 years old age, average (55.6 ± 9.1) year.The object of observation is respectively organized age, sex there are no significant difference (P＞0.05).
Each testing result of organizing PS PAI-1 C-RP and NO sees Table 1.
Table 1 is respectively organized PS PAI-1C-RP and NO content synopsis
Annotate: 1) with A group 0 all relatively P＜0.05,2) compare P＜0.05 with 4 weeks of C group; 3) compare P＜0.01 with 0 week of D group.
Each is organized lipids detection and the results are shown in Table 2.
Statistical result shows that UAP patient's blood plasma Ps, PAI-1, C-RP, OX-LDL, TC, LDL-C, TG level are obviously set up (P＜0.05), and blood plasma NO obviously reduces (P＜0.05).D group energy significance reduces UAP blood plasma Ps, PAI-1, C-RP, OX-LDL, TC, LDL-C, TG level, rising serum NO level level, and 4 weeks of D group are relatively all with 0, and significant difference (P＜0.01) is arranged; Compare with the C group, the D group can significantly reduce Ps, PAI-1, NO level (P＜0.05); Each organizes the HDL-C that all raises in various degree UAP, but not statistically significant (P＞0.05).
Table 2 is respectively organized lipid determination synopsis as a result
Annotate: 1) compare P＜0.05 with 0 week of A group; 2) compare P＜0.01 with 0 week of D group.
UAP blood plasma Ps level and other index related analysis
Ps and PAI-1, C-RP, OX-LDL level are remarkable positive correlation (r=0.466, r=0.512, r=0.537, P are all＜0.05), and Ps and NO are remarkable negative correlation (r=-0.520, P＜0.05).
Unstable angina pectoris of coronary heart disease belongs to traditional Chinese medical science thoracic obstruction category.The chest-rheumatism position relates to the five internal organs at the heart, is the card of deficiency in origin and excess in superficiality, and it loses emptyly for healthy energy, and it is turbid etc. to be designated as blood stasis, expectorant.Control with symptomatic treatment in acute condition, radical treatment in chronic case, giving consideration to both the incidental and fundamental are principle.The blood stasis dispersing and phlegm expelling prescription is made up of Radix Codonopsis, Herb Gynostemmae Pentaphylli, Poria, Rhizoma Acori Graminei etc., has the effect of invigorating the spleen and benefiting QI, dissipating phlegm and removing blood stasis.Reuse Radix Codonopsis, Herb Gynostemmae Pentaphylli invigorating the spleen and benefiting QI in the side, the lung being the utensil for storing phlegm, the spleen being the source of producing phlegm, Herb Gynostemmae Pentaphylli can spleen invigorating dehumidifying, to stop to give birth to the source of expectorant, again can preventing phlegm from forming and stopping coughing, with the device of respectful clean storage expectorant; Cooperate the Poria can spleen invigorating, again can eliminating dampness by diuresis, making wet do not have gather the expectorant life of having no way of; The Radix Salviae Miltiorrhizae merit is arrogated to oneself blood circulation promoting and blood stasis dispelling, for controlling the key medicine of stagnation of blood stasis; Assistant with Rhizoma Acori Graminei, Radix Curcumae,, the stomach function regulating that reduces phlegm, blood-activating and qi-promoting makes mechanism of qi unimpeded.All medicines share, altogether Qin's merit of blood stasis dispelling of eliminating the phlegm.Then body fluid is logical certainly to make the stasis of bloodization, and expectorant is evil in diffusing, the diffusing then venation tonneau of expectorant, and the stasis of blood can not be given birth to.Modern pharmacological research proves that Herb Gynostemmae Pentaphylli has tangible effect for reducing blood fat; Radix Codonopsis has the effect that suppresses the animal platelet aggregation; Radix Salviae Miltiorrhizae can improve hemorheological property, and blood viscosity lowering activates fibrinolytic anticoagulant, and anticoagulant and adhesiveness improve cAMP content in the platelet, antagonism thrombosis.
In the acute process of coronary heart disease, platelet activation is a key factor, and the abnormal change of blood coagulation and fibrinolytic system is one of major reason that causes coronary thrombosis formation.Blood plasma Ps can be used as a new specific index of platelet activation clinically, and activated blood platelet can be by discharging PAI-1 with the active further weakening of the fibrinolytic system of body.Also there is dependency as the plasma C-RP of acute inflammatory reaction thing sign and the generation and the development of coronary heart disease.The variation of OX-LDL and NO level is the principal element of reflection patients with coronary heart disease body lipid oxidative damage and endothelial function situation in the blood.The increase of OX-LDL in the blood vessel has been quickened and the combining and the formation of foam cell and the increase of fat nuclear of macrophage, causes the instability of atheromatous plaque.The stable factor of N candle arteria coronaria atheromatous plaque, under the environment of tremulous pulse medicated porridge sample pathological changes, endotheliocyte is to the synthetic decline of NO, and the serum NO level level reduces, and NO descends to the inhibitory action of Ps, and the inflammatory reaction of blood vessel medicated porridge sample lesion increases.Originally discover that UAP patient's blood plasma Ps, PAI-1, C-RP, OX-LDL level obviously increase, the serum NO level level significantly reduces, and conforms to bibliographical information.
This research prompting, platelet activation, fibrinolytic mechanism are unusual, the inflammatory reaction fellowship of lipid peroxidation, endothelial function imbalance and arteria coronaria blood vessel generation and the development of UAP.The blood stasis dispersing and phlegm expelling prescription can suppress Ps and activate, and eliminates platelet activation, blocks thrombotic initiating agent; And by suppressing platelet activation, PAI is discharged be suppressed, impel factor minimizing with fixed attention, thereby protected the fibrinolytic system activity of body; The blood stasis dispersing and phlegm expelling prescription also has the effect of anti peroxidation of lipid, protection blood vessel endothelium and the reaction of blocking-up vascular inflammation.
1, the blood stasis dispersing and phlegm expelling prescription can be prevented arachidonic acid pathway, ADP approach, the inductive hematoblastic activation of thrombin approach, especially arachidonic acid pathway.
2, α P that membrana granulosa discharges selected plain level after the blood stasis dispersing and phlegm expelling prescription can reduce platelet activation, had reduced hematoblastic activation and thrombosis, and preventing with P selection element is the local inflammation reaction of mediation.
3, the blood stasis dispersing and phlegm expelling prescription can improve vascular endothelial function.
4, the blood stasis dispersing and phlegm expelling prescription improves the imbalance of vascular endothelial function, thereby prevents the process of AS by suppressing hematoblastic activation, local inflammation reaction.
Claims (7)
1. a medicine for the treatment of coronary heart disease is characterized in that it being by Radix Codonopsis 9～30g; The Radix Astragali 9～30g; Poria 9～20g; Rhizoma Pinelliae Preparatum 3～10g; Rhizoma Acori Graminei 3～10g; Rhizoma Chuanxiong 3～15g; Radix Curcumae 3～15g; Radix Salviae Miltiorrhizae 5～15g; Herb Gynostemmae Pentaphylli 9～15g makes.
2. a kind of medicine for the treatment of coronary heart disease according to claim 1 is characterized in that being made up of Radix Codonopsis 25g, Radix Astragali 25g, Herb Gynostemmae Pentaphylli 15g, Poria 10g, Rhizoma Pinelliae Preparatum 5g, Rhizoma Acori Graminei 5g, Rhizoma Chuanxiong 5g, Radix Curcumae 5g, Radix Salviae Miltiorrhizae 5g.
3. a kind of medicine for the treatment of coronary heart disease according to claim 1 is characterized in that being made up of Radix Codonopsis 20g, Radix Astragali 20g, Herb Gynostemmae Pentaphylli 15g, Poria 15g, Rhizoma Pinelliae Preparatum 5g, Rhizoma Acori Graminei 5g, Rhizoma Chuanxiong 10g, Radix Curcumae 10g, Radix Salviae Miltiorrhizae 10g.
4. a kind of medicine for the treatment of coronary heart disease according to claim 1 is characterized in that being made up of Radix Codonopsis 15g, Radix Astragali 15g, Herb Gynostemmae Pentaphylli 15g, Poria 10g, Rhizoma Pinelliae Preparatum 5g, Rhizoma Acori Graminei 5g, Rhizoma Chuanxiong 15g, Radix Curcumae 15g, Radix Salviae Miltiorrhizae 15g.
5. a kind of medicine for the treatment of coronary heart disease according to claim 1 is characterized in that being made up of Radix Codonopsis 10g, Radix Astragali 10g, Herb Gynostemmae Pentaphylli 15g, Poria 15g, Rhizoma Pinelliae Preparatum 5g, Rhizoma Acori Graminei 5g, Rhizoma Chuanxiong 15g, Radix Curcumae 10g, Radix Salviae Miltiorrhizae 10g.
6. a kind of medicine for the treatment of coronary heart disease according to claim 1 is characterized in that being made up of Radix Codonopsis 10g, Radix Astragali 10g, Herb Gynostemmae Pentaphylli 15g, Poria 15g, Rhizoma Pinelliae Preparatum 5g, Rhizoma Acori Graminei 5g, Rhizoma Chuanxiong 15g, Radix Curcumae 15g, Radix Salviae Miltiorrhizae 15g.
7. a kind of medicine for the treatment of coronary heart disease according to claim 1 is characterized in that being made up of Radix Codonopsis 10g, Radix Astragali 10g, Herb Gynostemmae Pentaphylli 15g, Poria 20g, Rhizoma Pinelliae Preparatum 10g, Rhizoma Acori Graminei 10g, Rhizoma Chuanxiong 15g, Radix Curcumae 15g, Radix Salviae Miltiorrhizae 15g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100108459A CN101279075B (en) | 2007-04-05 | 2007-04-05 | Medicament for curing coronary heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100108459A CN101279075B (en) | 2007-04-05 | 2007-04-05 | Medicament for curing coronary heart disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101279075A true CN101279075A (en) | 2008-10-08 |
| CN101279075B CN101279075B (en) | 2011-09-28 |
Family
ID=40011864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100108459A Active CN101279075B (en) | 2007-04-05 | 2007-04-05 | Medicament for curing coronary heart disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101279075B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103110876A (en) * | 2012-12-10 | 2013-05-22 | 宋爱民 | Traditional Chinese medicine preparation for treating heart qi deficiency type bradycardia |
| CN104043063A (en) * | 2014-07-14 | 2014-09-17 | 徐涛 | Traditional Chinese medicine capable of treating coronary heart disease |
| CN104435635A (en) * | 2014-11-26 | 2015-03-25 | 刘宁 | Traditional Chinese medicine composition for treating postmenopausal coronary heart disease |
| CN109464632A (en) * | 2018-12-27 | 2019-03-15 | 同溢堂药业有限公司 | A kind of drug and preparation method thereof for treating coronary heart disease |
| CN109549995A (en) * | 2019-01-18 | 2019-04-02 | 张掖市金盛中药饮片有限公司 | It is a kind of for treating the pulvis of coronary heart disease |
| CN112755149A (en) * | 2020-12-30 | 2021-05-07 | 西安交通大学医学院第一附属医院 | Traditional Chinese medicine composition for treating coronary heart disease and preparation method and application thereof |
-
2007
- 2007-04-05 CN CN2007100108459A patent/CN101279075B/en active Active
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103110876A (en) * | 2012-12-10 | 2013-05-22 | 宋爱民 | Traditional Chinese medicine preparation for treating heart qi deficiency type bradycardia |
| CN104043063A (en) * | 2014-07-14 | 2014-09-17 | 徐涛 | Traditional Chinese medicine capable of treating coronary heart disease |
| CN104435635A (en) * | 2014-11-26 | 2015-03-25 | 刘宁 | Traditional Chinese medicine composition for treating postmenopausal coronary heart disease |
| CN104435635B (en) * | 2014-11-26 | 2018-07-24 | 刘宁 | It is a kind of to treat Menopause uterine hemorrhage Chinese medicine composition |
| CN109464632A (en) * | 2018-12-27 | 2019-03-15 | 同溢堂药业有限公司 | A kind of drug and preparation method thereof for treating coronary heart disease |
| CN109549995A (en) * | 2019-01-18 | 2019-04-02 | 张掖市金盛中药饮片有限公司 | It is a kind of for treating the pulvis of coronary heart disease |
| CN112755149A (en) * | 2020-12-30 | 2021-05-07 | 西安交通大学医学院第一附属医院 | Traditional Chinese medicine composition for treating coronary heart disease and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101279075B (en) | 2011-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101279075B (en) | Medicament for curing coronary heart disease | |
| CN101700358A (en) | Medicine for treating acute and chronic nonspecific ulcerative colitis and preparation method thereof | |
| CN102205090A (en) | Chinese medicinal stagnancy-removing and stagnation-eliminating soup for treating liver depression qi stagnation type indigestion | |
| CN110478452A (en) | A kind of Chinese medicine composition and preparation method thereof for treating gout | |
| CN103520659B (en) | Traditional Chinese medicine for treating cancer | |
| CN102552520B (en) | Blood circulation-promoting and pain-stopping medicament and preparation process and application thereof | |
| CN103142844A (en) | Pharmaceutical composition for treating diabetic nephropathy | |
| CN105456652B (en) | A kind of Chinese materia medica preparation and preparation method thereof for treating dyslipidemia and coronary heart disease | |
| CN101653550B (en) | Chinese medicinal composition in preparation of medicament for treating type II diabetes | |
| CN104147346A (en) | Traditional Chinese medicinal compound for treating coronary diffuse lesion angina | |
| CN103908490A (en) | Pure plant traditional Chinese medicinal preparation for treating myocardial infarction and cardiovascular diseases and preparation method thereof | |
| CN103041119A (en) | Traditional Chinese medicine for treating cardiac disease | |
| CN102302708A (en) | Medicament for chronic kidney disease (kidney deficiency and blood stasis) | |
| CN102631502B (en) | Medicament for preventing and treating atherosclerosis and preparation method of granular formulation | |
| CN101947299B (en) | Medicinal composition for treating coronary heart disease | |
| CN107693593B (en) | Traditional Chinese medicine composition for preventing and treating coronary heart disease | |
| CN104258351A (en) | Traditional Chinese medicine preparation for treating alcoholic cardiomyopathy and preparation method of preparation | |
| CN103893694B (en) | A kind of medicine for treating coronary heart disease | |
| CN105560911B (en) | A kind of Chinese medicine and preparation method thereof for treating hypertension | |
| CN104645247B (en) | A kind of Chinese medicine preparation for treating hepatolenticular degeneration and preparation method thereof | |
| CN105079503A (en) | Traditional Chinese medicine for dredging blood vessels | |
| CN101411814B (en) | Use of Chinese medicinal composition in preparing medicament for treating intraventricular block | |
| CN107661422B (en) | Traditional Chinese medicine composition for preventing and treating coronary heart disease and preparation method thereof | |
| CN104258309A (en) | Traditional Chinese medicine composition for treating cancers | |
| CN1951457A (en) | Chinese medicinal preparation for treating proteinuria caused by diabetic nephropathy and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |